PT91294A - Processo para a preparacao de construtos de antigenes a partir de antigenes da classe i de "complexo de histocompatibilidade principal" com moleculas de suporte especificas e de composicoes farmaceuticas que os comtem - Google Patents
Processo para a preparacao de construtos de antigenes a partir de antigenes da classe i de "complexo de histocompatibilidade principal" com moleculas de suporte especificas e de composicoes farmaceuticas que os comtemInfo
- Publication number
- PT91294A PT91294A PT91294A PT9129489A PT91294A PT 91294 A PT91294 A PT 91294A PT 91294 A PT91294 A PT 91294A PT 9129489 A PT9129489 A PT 9129489A PT 91294 A PT91294 A PT 91294A
- Authority
- PT
- Portugal
- Prior art keywords
- antigens
- class
- major histocompatibility
- histocompatibility complex
- antigen constructs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3825615A DE3825615A1 (de) | 1988-07-28 | 1988-07-28 | Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung |
Publications (2)
Publication Number | Publication Date |
---|---|
PT91294A true PT91294A (pt) | 1990-02-08 |
PT91294B PT91294B (pt) | 1995-03-01 |
Family
ID=6359731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT91294A PT91294B (pt) | 1988-07-28 | 1989-07-27 | Processo para a preparacao de construtos de antigenes a partir de antigenes da classe i de "complexo de histocompatibilidade principal" com moleculas de suporte especificas e de composicoes farmaceuticas que os comtem |
Country Status (12)
Country | Link |
---|---|
US (2) | US6548067B1 (pt) |
EP (1) | EP0352761B1 (pt) |
JP (1) | JP2812726B2 (pt) |
KR (1) | KR970010760B1 (pt) |
AT (1) | ATE128732T1 (pt) |
AU (1) | AU625065B2 (pt) |
DE (2) | DE3825615A1 (pt) |
DK (1) | DK371089A (pt) |
ES (1) | ES2080055T3 (pt) |
FI (1) | FI100973B (pt) |
GR (1) | GR3017915T3 (pt) |
PT (1) | PT91294B (pt) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525338A (en) * | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
DE3825615A1 (de) * | 1988-07-28 | 1990-02-01 | Behringwerke Ag | Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DE4106389A1 (de) * | 1991-02-28 | 1992-09-03 | Behringwerke Ag | Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung |
US7241595B2 (en) | 1989-10-20 | 2007-07-10 | Sanofi-Aventis Pharma Deutschland Gmbh | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates |
SE9002484L (sv) | 1990-07-20 | 1992-01-21 | Kabi Pharmacia Ab | Nya substituerade polyetrar |
US5885570A (en) * | 1991-01-23 | 1999-03-23 | The General Hospital Corporation | Induction of tolerance with modified immunogens |
JP3105629B2 (ja) † | 1991-04-23 | 2000-11-06 | サングスタット メディカル コーポレイション | 特異的結合ペアのメンバーの細胞活性調節接合体 |
DE4133791A1 (de) * | 1991-10-11 | 1993-04-15 | Behringwerke Ag | Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung |
JPH05246889A (ja) * | 1992-03-05 | 1993-09-24 | Seitai Chiyousetsu Kenkyusho:Kk | 制癌方法および制癌剤 |
US6030797A (en) * | 1992-10-08 | 2000-02-29 | Dade Behring Marburg Gmbh | Monoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereof |
WO1997024446A2 (en) * | 1995-12-29 | 1997-07-10 | Chiron Corporation | Gene delivery vehicle-targeting ligands |
CA2250166A1 (en) | 1996-03-28 | 1997-10-02 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
US6211342B1 (en) * | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
JP2001500479A (ja) * | 1996-08-23 | 2001-01-16 | マサチューセッツ インスティチュート オブ テクノロジー | 細胞破壊のメディエーターとしての同種異系組織適合性複合体 |
US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
US20020051783A1 (en) * | 1998-06-05 | 2002-05-02 | Savage Philip Michael | Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means |
AU2002301994B2 (en) * | 1998-06-05 | 2008-05-15 | Alexis Biotech Limited | Method for producing cytotoxic T-cells |
GB2339782A (en) * | 1998-06-05 | 2000-02-09 | Philip Michael Savage | Chimeric protein complexes comprising HLA class I antigens |
US7521197B2 (en) | 1998-06-05 | 2009-04-21 | Alexis Biotech Limited | Method for producing cytotoxic T-cells |
US7264965B2 (en) | 1998-06-05 | 2007-09-04 | Alexis Biotech Limited | Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means |
US6197591B1 (en) * | 1998-09-14 | 2001-03-06 | Pfizer Inc. | Streptomyces avermitilis regulatory genes for increased avermectin production |
IL151860A0 (en) * | 2000-03-27 | 2003-04-10 | Technion Res & Dev Foundation | Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
WO2001074382A1 (en) | 2000-03-31 | 2001-10-11 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
AU2001255326B2 (en) * | 2000-04-12 | 2005-12-15 | University Of Rochester | Targeted vaccine delivery systems |
DK2336167T3 (da) * | 2001-03-14 | 2019-09-02 | Dako Denmark As | MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi |
US8022190B2 (en) | 2001-06-19 | 2011-09-20 | Technion Research & Development Foundation Ltd. | Immuno-molecules containing viral proteins, compositions thereof and methods of using |
US20030017134A1 (en) * | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
CA2493081C (en) * | 2002-07-12 | 2013-04-23 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
US20040210037A1 (en) * | 2003-03-28 | 2004-10-21 | Vaccinex, Inc. | Targeted MHC class I alpha3 vaccine delivery systems |
US20050042218A1 (en) * | 2003-07-10 | 2005-02-24 | Vaccinex, Inc. | MHC class I - peptide-antibody conjugates with modified beta2-microglobulin |
GB2408507B (en) * | 2003-10-06 | 2005-12-14 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof for specific targeting |
GB2409456B (en) * | 2003-10-30 | 2006-01-04 | Proimmune Ltd | Oligomeric receptor ligand pair member complexes |
US20050287611A1 (en) * | 2004-05-07 | 2005-12-29 | Nugent C T Iv | MHC bridging system for detecting CTL-mediated lysis of antigen presenting cells |
WO2007085266A1 (en) * | 2006-01-30 | 2007-08-02 | Dako Denmark A/S | High-speed quantification of antigen specific t-cells in whole blood by flow cytometry |
CN101448951B (zh) * | 2006-05-19 | 2013-04-10 | 泰华制药工业有限公司 | 融合蛋白、其用途以及制备方法 |
GB2442048B (en) * | 2006-07-25 | 2009-09-30 | Proimmune Ltd | Biotinylated MHC complexes and their uses |
JP5357782B2 (ja) | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷CD1d分子によるNKT細胞活性の調節 |
EP2361930A3 (en) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
EP3023436A1 (en) * | 2007-07-03 | 2016-05-25 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
WO2009039854A2 (en) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
US10722562B2 (en) | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US9139809B2 (en) | 2009-01-08 | 2015-09-22 | Albert Einstein College Of Medicine Of Yeshiva University | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
SG195077A1 (en) * | 2011-06-22 | 2013-12-30 | Hoffmann La Roche | Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes |
KR20150088881A (ko) * | 2012-11-30 | 2015-08-03 | 로슈 글리카트 아게 | 암세포 표적화된 mhc 클래스 i 포함 다중기능 단백질을 사용하는 순환 바이러스-특이적 세포독성 t-세포에 의한 암세포의 제거 |
JP6475167B2 (ja) | 2012-12-21 | 2019-02-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィド結合した多価mhcクラスiを含む多機能タンパク質 |
US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0006916B1 (en) * | 1977-09-28 | 1981-07-08 | National Research Development Corporation | Immunological preparations incorporating mhc antigens and their production |
EP0031812B1 (en) * | 1979-03-27 | 1983-06-15 | National Research Development Corporation | Improvements in or relating to immunological preparations |
DE3329184A1 (de) * | 1983-08-12 | 1985-02-21 | Behringwerke Ag, 3550 Marburg | Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene |
DE3531301A1 (de) * | 1985-09-02 | 1987-03-05 | Behringwerke Ag | Monoklonale antikoerper gegen tumorassoziierte glykoproteine, verfahren zu ihrer herstellung sowie ihre verwendung |
US4894443A (en) * | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
DE3545576A1 (de) * | 1985-11-28 | 1987-07-02 | Behringwerke Ag | Hla-b 27, dafuer codierende genomische dna und ihre verwendung |
US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
EP0334300A1 (en) | 1988-03-21 | 1989-09-27 | Neorx Corporation | The use of monoclonal antibodies and conjugates thereof as signals to direct sensitized effector cells to tumor sites |
US5130297A (en) * | 1988-06-23 | 1992-07-14 | Anergen, Inc. | Conjugates useful in ameliorating autoimmunity MHC-II-peptide |
US5194425A (en) * | 1988-06-23 | 1993-03-16 | Anergen, Inc. | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
DE3825615A1 (de) * | 1988-07-28 | 1990-02-01 | Behringwerke Ag | Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
-
1988
- 1988-07-28 DE DE3825615A patent/DE3825615A1/de not_active Withdrawn
-
1989
- 1989-07-25 EP EP89113741A patent/EP0352761B1/de not_active Expired - Lifetime
- 1989-07-25 AT AT89113741T patent/ATE128732T1/de not_active IP Right Cessation
- 1989-07-25 DE DE58909458T patent/DE58909458D1/de not_active Expired - Fee Related
- 1989-07-25 ES ES89113741T patent/ES2080055T3/es not_active Expired - Lifetime
- 1989-07-26 FI FI893575A patent/FI100973B/fi not_active IP Right Cessation
- 1989-07-27 KR KR1019890010629A patent/KR970010760B1/ko not_active IP Right Cessation
- 1989-07-27 AU AU39005/89A patent/AU625065B2/en not_active Ceased
- 1989-07-27 DK DK371089A patent/DK371089A/da unknown
- 1989-07-27 PT PT91294A patent/PT91294B/pt not_active IP Right Cessation
- 1989-07-28 JP JP1196476A patent/JP2812726B2/ja not_active Expired - Lifetime
-
1995
- 1995-06-02 US US08/460,569 patent/US6548067B1/en not_active Expired - Fee Related
- 1995-10-30 GR GR950403017T patent/GR3017915T3/el unknown
-
2003
- 2003-04-14 US US10/412,672 patent/US20040091488A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR970010760B1 (ko) | 1997-06-30 |
AU625065B2 (en) | 1992-07-02 |
ES2080055T3 (es) | 1996-02-01 |
FI100973B (fi) | 1998-03-31 |
US6548067B1 (en) | 2003-04-15 |
EP0352761A3 (de) | 1991-09-04 |
US20040091488A1 (en) | 2004-05-13 |
DE3825615A1 (de) | 1990-02-01 |
ATE128732T1 (de) | 1995-10-15 |
EP0352761B1 (de) | 1995-10-04 |
DK371089A (da) | 1990-01-29 |
JPH02104599A (ja) | 1990-04-17 |
FI893575A0 (fi) | 1989-07-26 |
KR910003098A (ko) | 1991-02-26 |
DK371089D0 (da) | 1989-07-27 |
FI893575A (fi) | 1990-01-29 |
DE58909458D1 (de) | 1995-11-09 |
GR3017915T3 (en) | 1996-01-31 |
EP0352761A2 (de) | 1990-01-31 |
PT91294B (pt) | 1995-03-01 |
AU3900589A (en) | 1990-02-01 |
JP2812726B2 (ja) | 1998-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT91294A (pt) | Processo para a preparacao de construtos de antigenes a partir de antigenes da classe i de "complexo de histocompatibilidade principal" com moleculas de suporte especificas e de composicoes farmaceuticas que os comtem | |
Lu et al. | Tutorial review. Oriented immobilization of antibodies and its applications in immunoassays and immunosensors | |
Labeta et al. | Structure of asymmetric non-precipitating antibody: presence of a carbohydrate residue in only one Fab region of the molecule. | |
Lowey et al. | An immunochemical approach to the structure of myosin and the thick filament | |
BR9608481A (pt) | Anticorpos quiméricos para administração de antìgenos a células selecionadas do sistema imunológico. | |
PT856520E (pt) | Metodo de preparacao de um anticorpo monoclonal, anticorpo monoclonal, uma composicao farmaceutica e um reagente de diagnostico | |
Ferguson et al. | Isolation and characterization of a T suppressor factor by using a monoclonal antibody. | |
ES2149159T3 (es) | Proteinas de fusion con contenido en anticuerpos monoclonales, enlazador- y beta-glucuronidasa, destinadas a la activacion de profarmacos, su preparacion y utilizacion. | |
Hesketh et al. | Immunohistochemical evidence for an association of ribosomes with microfilaments in 3T3 fibroblasts | |
Gordon et al. | Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. I. Characterization with syngeneic and xenogeneic complements. | |
Parkhouse | Non-covalent association of IgM subunits produced by reduction and alkylation | |
ATE197709T1 (de) | Methadonderivate und protein- und polypeptid- methadonkonjugate und markierte verbindungen | |
DK0464101T3 (da) | Forbedringer ved radioaktiv mærkning af proteiner | |
JPS61234779A (ja) | 細胞毒性tリンパ球により溶解を受け得る標的細胞の製造法 | |
ATE395422T1 (de) | Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems | |
Warner et al. | Detection of two species of antibody molecules with the same specificity | |
ATE125305T1 (de) | Monoklonale antikörper von ratten gegen menschliche antigene und verfahren zu deren herstellung. | |
Schröter-Kermani et al. | An inhibition ELISA for the quantification of collagens type I and type II in cyanogen bromide-digested tissues using fragment-directed antibodies | |
Leu et al. | Photometric assays for FcRI-dependent binding, phagocytosis, and antibody-dependent cellular cytotoxicity mediated by monomeric IgGγ2a in murine peritoneal macrophages | |
DE68906758T2 (de) | Immunoadsorbens mit geringer Freisetzungsrate und Verfahren zu seiner Herstellung. | |
NO974793L (no) | Fremgangsmåte til fremstilling av et monoklonalt antistoff mot Onkostatin M, eller et fragment derav | |
Stebbings et al. | MAPs and motors in insect ovaries | |
FR2642072A1 (fr) | Adsorbants thiophiliques | |
KR930701201A (ko) | 면역반응성 화합물 | |
WO1988007200A1 (en) | Monoclonal antibody conjugation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG3A | Patent granted, date of granting |
Effective date: 19940817 |
|
MM3A | Annulment or lapse |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20020228 |